Tomás Dias
Research Subjects
Tomás Dias has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Paulo Peixeiro Freitas
Instituto de Engenharia de Sistemas e Computadores—Microsistemas e Nanotecnologias (INESC MN)
4 shared publications - Susana Cardoso
Instituto de Engenharia de Sistemas e Computadores—Microsistemas e Nanotecnologias (INESC MN)
4 shared publications Elnaz Persia
Mursla Bio Cambridge UK
3 shared publications- Pierre Arsène
Mursla Bio Cambridge UK
3 shared publications Ricardo Figueiras
Mursla Bio Cambridge UK
3 shared publicationsSusana Vagueiro
Mursla Bio Cambridge UK
3 shared publications
Latest Publications
- Open Access
- 10 October 2026
- Published by Wiley in Journal of Extracellular Vesicles
- Vol. 15 (10) , e70372
Tissue‐Specific Isolation of Hepatocyte Extracellular Vesicles From Human Plasma Enables Tissue‐Resolved Proteomic and miRNA Profiling
Tissue‐specific resolution remains a critical barrier in liquid biopsy for precision medicine. To address this, we developed NEXPLOR (Novel EXtracellular vesicle PopuLation Omics Revealer), an immunoaffinity platform enabling selective enrichment of circulating tissue‐specific extracellular vesicles (TS‐EVs), demonstrated here for liver‐derived hepatocyte‐EVs (h‐EVs). Through in silico discovery and orthogonal antibody validation across tissues, we identified a four‐marker panel (ASGR1, ASGR2, TFR2, SLCO1B1) that selectively enriched hepatocyte EVs without co‐capturing the dominant platelet‐ and leukocyte‐EV background. In a clinical cohort of hepatocellular carcinoma (HCC), non‐cancer cirrhosis and healthy donors, NEXPLOR recovered 57% more proteins than bulk EV isolation, with greater reproducibility. By restoring tissue context, h‐EVs exposed liver biology that bulk EVs miss, spanning three levels: metabolic pathways (carbon metabolism, HIF‐1α signalling, ferroptosis), HCC‐defining proteins (PGD, H2AZ1, PRDX5), and progression‐tracking candidates (CFB, PCSK9). Small RNA sequencing detected five miRNAs upregulated in HCC versus cirrhosis h‐EVs, against 21 in bulk EVs (no overlap); yet only the h‐EV miRNAs mapped to HCC‐relevant signalling, and hepatocyte‐regulatory miR‐124‐3p appeared exclusively in h‐EVs. Together, these results establish tissue‐specific EV enrichment as a route to more actionable, multi‐omic liquid biopsies in HCC, cirrhosis and other diseases in urgent need of non‐invasive biomarkers for patient diagnosis, monitoring and stratification.
- 10 October 2026
- Published by Wiley in Journal of Extracellular Vesicles
- Vol. 15 (10) , e70372
Open AccessTissue‐Specific Isolation of Hepatocyte Extracellular Vesicles From Human Plasma Enables Tissue‐Resolved Proteomic and miRNA Profiling
Tissue‐specific resolution remains a critical barrier in liquid biopsy for precision medicine. To address this, we developed NEXPLOR (Novel EXtracellular vesicle PopuLation Omics Revealer), an immunoaffinity platform enabling selective enrichment of circulating tissue‐specific extracellular vesicles (TS‐EVs), demonstrated here for liver‐derived hepatocyte‐EVs (h‐EVs). Through in silico discovery and orthogonal antibody validation across tissues, we identified a four‐marker panel (ASGR1, ASGR2, TFR2, SLCO1B1) that selectively enriched hepatocyte EVs without co‐capturing the dominant platelet‐ and leukocyte‐EV background. In a clinical cohort of hepatocellular carcinoma (HCC), non‐cancer cirrhosis and healthy donors, NEXPLOR recovered 57% more proteins than bulk EV isolation, with greater reproducibility. By restoring tissue context, h‐EVs exposed liver biology that bulk EVs miss, spanning three levels: metabolic pathways (carbon metabolism, HIF‐1α signalling, ferroptosis), HCC‐defining proteins (PGD, H2AZ1, PRDX5), and progression‐tracking candidates (CFB, PCSK9). Small RNA sequencing detected five miRNAs upregulated in HCC versus cirrhosis h‐EVs, against 21 in bulk EVs (no overlap); yet only the h‐EV miRNAs mapped to HCC‐relevant signalling, and hepatocyte‐regulatory miR‐124‐3p appeared exclusively in h‐EVs. Together, these results establish tissue‐specific EV enrichment as a route to more actionable, multi‐omic liquid biopsies in HCC, cirrhosis and other diseases in urgent need of non‐invasive biomarkers for patient diagnosis, monitoring and stratification.
- Open Access
Organ-specific isolation of hepatocyte extracellular vesicles from human plasma enables tissue-resolved proteomic and miRNA profiling
Tissue-specific resolution remains a key limitation in liquid biopsy to achieve the highest accuracy for precision medicine. To address this limitation, we developed NEXPLOR (Novel EXtracellular vesicle PopuLation and Omics Revealer), a magnetic bead-based platform enabling selective immuno-isolation of tissue-derived EVs. Focusing on hepatocyte-derived EVs (h-EVs), we demonstrate NEXPLOR’s specificity and sensitivity in capturing rare EV subpopulations directly from human plasma. Using in silico tissue marker discovery, we identified and validated a TOP4 capture antibody panel (ASGR1, ASGR2, TFR2, SLCO1B1) for h-EV isolation through an ultrasensitive orthogonal method (O-NEXOS). Applied to liver disease using clinical plasma samples, NEXPLOR enabled deeper and more reproducible proteomic profiling compared to matched bulk EVs, revealing liver-specific and disease-relevant pathways, including ferroptosis, HIF-1α signaling, and central carbon metabolism in cancer. Moreover, small RNA sequencing uncovered a reduced but highly informative set of miRNAs, including miR-124-3p and miR-23b-3p , differentially expressed in hepatocellular carcinoma (HCC) compared to cirrhosis, and undetectable in bulk EVs. These molecular signatures suggest disease state based on real-time hepatocyte biology. Our findings establish NEXPLOR as a robust platform for tissue-specific EV capture, enabling tissue-resolved, multi-omic biomarker discovery. This opens new frontiers in early disease detection, longitudinal monitoring, and AI-powered biomarker discovery for precision medicine.
Open AccessOrgan-specific isolation of hepatocyte extracellular vesicles from human plasma enables tissue-resolved proteomic and miRNA profiling
Tissue-specific resolution remains a key limitation in liquid biopsy to achieve the highest accuracy for precision medicine. To address this limitation, we developed NEXPLOR (Novel EXtracellular vesicle PopuLation and Omics Revealer), a magnetic bead-based platform enabling selective immuno-isolation of tissue-derived EVs. Focusing on hepatocyte-derived EVs (h-EVs), we demonstrate NEXPLOR’s specificity and sensitivity in capturing rare EV subpopulations directly from human plasma. Using in silico tissue marker discovery, we identified and validated a TOP4 capture antibody panel (ASGR1, ASGR2, TFR2, SLCO1B1) for h-EV isolation through an ultrasensitive orthogonal method (O-NEXOS). Applied to liver disease using clinical plasma samples, NEXPLOR enabled deeper and more reproducible proteomic profiling compared to matched bulk EVs, revealing liver-specific and disease-relevant pathways, including ferroptosis, HIF-1α signaling, and central carbon metabolism in cancer. Moreover, small RNA sequencing uncovered a reduced but highly informative set of miRNAs, including miR-124-3p and miR-23b-3p , differentially expressed in hepatocellular carcinoma (HCC) compared to cirrhosis, and undetectable in bulk EVs. These molecular signatures suggest disease state based on real-time hepatocyte biology. Our findings establish NEXPLOR as a robust platform for tissue-specific EV capture, enabling tissue-resolved, multi-omic biomarker discovery. This opens new frontiers in early disease detection, longitudinal monitoring, and AI-powered biomarker discovery for precision medicine.
- Open Access
An electro-optical bead-nanochip technology for the ultrasensitive and multi-dimensional detection of small extracellular vesicles and their markers
Small extracellular vesicles (sEVs), including exosomes, are enriched in multiomics information mirroring their parental cells. They have been investigated in health and disease and utilised in several applications from drug discovery to diagnostics. In disease diagnostics, sEVs can be sampled via a blood draw, enabling the convenient liquid biopsy of the tissue they originate from. However, few applications with sEVs have been translated into clinical practice. We developed a Nanoparticle EXOsome Sensing (NEXOS) technology, for the ultrasensitive and multi-dimensional detection of sEVs. NEXOS comprises two methods: a novel nanoelectronics method, E-NEXOS, and a high-throughput optical detection method, O-NEXOS. Both methods share the same steps for the immunocapture and antibody-labelling of sEVs and can be combined to derive differentiated detection parameters. As a proof of concept, we show the analytical detection and sensitivity of these methods in detecting pre-prepared cancer cell-derived CD9 + CD81 + and CD9 + HER2 + sEVs. Both sEV populations were diluted in PBS and spiked in processed plasma. We also provide a novel approach for the determination of target sEVs (TEVs), target epitopes in sEVs (TEPs), and epitopes per target sEV, as yet unseen from current and emerging technologies. Further, we demonstrate the higher sensitivity of O-NEXOS compared to the gold standard techniques, as well as demonstrating that E-NEXOS possesses commensurate sensitivity whilst only being powered by 36 nanogap-based sensors per nanochip. Finally, this manuscript lays the groundwork for a scalable electronics miniaturization of E-NEXOS nanochip with millions of nanogap-based sensors for the translation of NEXOS into standard clinical practice.
Open AccessAn electro-optical bead-nanochip technology for the ultrasensitive and multi-dimensional detection of small extracellular vesicles and their markers
Small extracellular vesicles (sEVs), including exosomes, are enriched in multiomics information mirroring their parental cells. They have been investigated in health and disease and utilised in several applications from drug discovery to diagnostics. In disease diagnostics, sEVs can be sampled via a blood draw, enabling the convenient liquid biopsy of the tissue they originate from. However, few applications with sEVs have been translated into clinical practice. We developed a Nanoparticle EXOsome Sensing (NEXOS) technology, for the ultrasensitive and multi-dimensional detection of sEVs. NEXOS comprises two methods: a novel nanoelectronics method, E-NEXOS, and a high-throughput optical detection method, O-NEXOS. Both methods share the same steps for the immunocapture and antibody-labelling of sEVs and can be combined to derive differentiated detection parameters. As a proof of concept, we show the analytical detection and sensitivity of these methods in detecting pre-prepared cancer cell-derived CD9 + CD81 + and CD9 + HER2 + sEVs. Both sEV populations were diluted in PBS and spiked in processed plasma. We also provide a novel approach for the determination of target sEVs (TEVs), target epitopes in sEVs (TEPs), and epitopes per target sEV, as yet unseen from current and emerging technologies. Further, we demonstrate the higher sensitivity of O-NEXOS compared to the gold standard techniques, as well as demonstrating that E-NEXOS possesses commensurate sensitivity whilst only being powered by 36 nanogap-based sensors per nanochip. Finally, this manuscript lays the groundwork for a scalable electronics miniaturization of E-NEXOS nanochip with millions of nanogap-based sensors for the translation of NEXOS into standard clinical practice.
- Open Access
- 7 September 2017
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 7 (68) , 43273-43282
One-step trapping of droplets and surface functionalization of sensors using gold-patterned structures for multiplexing in biochips
Multiplexing in Point-of-Care (POC) diagnostics is crucial for a comprehensive readout of multifactorial diseases such as cancer or fast-acting complications such as heart attacks. In multiplexed POC (MPOC) testing, groups of sensors are functionalized with different biological probes, enabling the simultaneous capture and detection of various analytes. Current literature demonstrates MPOC systems using microfluidics, capable of compartmentalizing only a few sensing regions. In contrast, miniaturized robotic spotting (microspotting) theoretically enables the independent functionalization of every sensor in a microarray. However, its use is still challenging in biosensors which require the combination of different materials at the surface because microspotted droplets tend to move to areas of higher surface energy, thus affecting the spotting precision. To counteract this phenomenon, we have combined shapes of gold-patterned films for the functionalization of magnetoresistive (MR) sensors and simultaneous trapping of droplets over the sensing regions, previously passivated with silicon nitride (Si3N4). Due to the higher hydrophobicity of gold when compared to Si3N4, the droplets remain immobilized inside the gold frames and functionalization of the sensors is accurately achieved. With this strategy, we demonstrate the microspotting of different DNA probes and antibodies and the specific hybridization and binding of complementary DNA targets and proteins, attached to magnetic beads. This combined trapping and functionalization system shows promise in the implementation of MR-based systems in multiplexing applications. This work can also be of interest to the wider community working in the development of other surface-based assays, also developed through microfabrication techniques, as the same trapping methodology is conceivable for adaption to other biochip formats.
- 7 September 2017
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 7 (68) , 43273-43282
Open AccessOne-step trapping of droplets and surface functionalization of sensors using gold-patterned structures for multiplexing in biochips
Multiplexing in Point-of-Care (POC) diagnostics is crucial for a comprehensive readout of multifactorial diseases such as cancer or fast-acting complications such as heart attacks. In multiplexed POC (MPOC) testing, groups of sensors are functionalized with different biological probes, enabling the simultaneous capture and detection of various analytes. Current literature demonstrates MPOC systems using microfluidics, capable of compartmentalizing only a few sensing regions. In contrast, miniaturized robotic spotting (microspotting) theoretically enables the independent functionalization of every sensor in a microarray. However, its use is still challenging in biosensors which require the combination of different materials at the surface because microspotted droplets tend to move to areas of higher surface energy, thus affecting the spotting precision. To counteract this phenomenon, we have combined shapes of gold-patterned films for the functionalization of magnetoresistive (MR) sensors and simultaneous trapping of droplets over the sensing regions, previously passivated with silicon nitride (Si3N4). Due to the higher hydrophobicity of gold when compared to Si3N4, the droplets remain immobilized inside the gold frames and functionalization of the sensors is accurately achieved. With this strategy, we demonstrate the microspotting of different DNA probes and antibodies and the specific hybridization and binding of complementary DNA targets and proteins, attached to magnetic beads. This combined trapping and functionalization system shows promise in the implementation of MR-based systems in multiplexing applications. This work can also be of interest to the wider community working in the development of other surface-based assays, also developed through microfabrication techniques, as the same trapping methodology is conceivable for adaption to other biochip formats.
- 27 April 2017
- Published by IOP Publishing in Journal of Physics D: Applied Physics
- Vol. 50 (21) , 213001
Challenges and trends in magnetic sensor integration with microfluidics for biomedical applications
Magnetoresistive (MR) sensors have been successfully applied in many technologies, in particular readout electronics and smart systems for multiple signal addressing and readout. When single sensors are used, the requirements relate to spatial resolution and localized field sources. The integration of MR sensors in adaptable media (e.g. flexible, stretchable substrates) offers the possibility to merge the magnetic detection with mechanical functionalities. In addition, the precision of a micrometric needle can benefit greatly from the integration of MR sensors with submicrometric resolution. In this paper, we demonstrate through several detailed examples how advanced MR sensors can be integrated with the systems described above, and also with microfluidic technologies. Here, the challenges of handling liquids over a chip combine with those for miniaturization of microelectronics for MR readout. However, when these are overcome, the result is an integrated system with added functionalities, capable of answering the demand in biomedicine and biochemistry for lab-on-a-chip devices.
- 27 April 2017
- Published by IOP Publishing in Journal of Physics D: Applied Physics
- Vol. 50 (21) , 213001
Challenges and trends in magnetic sensor integration with microfluidics for biomedical applications
Magnetoresistive (MR) sensors have been successfully applied in many technologies, in particular readout electronics and smart systems for multiple signal addressing and readout. When single sensors are used, the requirements relate to spatial resolution and localized field sources. The integration of MR sensors in adaptable media (e.g. flexible, stretchable substrates) offers the possibility to merge the magnetic detection with mechanical functionalities. In addition, the precision of a micrometric needle can benefit greatly from the integration of MR sensors with submicrometric resolution. In this paper, we demonstrate through several detailed examples how advanced MR sensors can be integrated with the systems described above, and also with microfluidic technologies. Here, the challenges of handling liquids over a chip combine with those for miniaturization of microelectronics for MR readout. However, when these are overcome, the result is an integrated system with added functionalities, capable of answering the demand in biomedicine and biochemistry for lab-on-a-chip devices.
- 21 February 2017
- Published by Royal Society of Chemistry (RSC) in The Analyst
- Vol. 142 (6) , 979-986
Rapid and specific detection of cell-derived microvesicles using a magnetoresistive biochip
Microvesicles (MVs) are a promising source of diagnostic biomarkers which have gained a wide interest in the biomedical and biosensing field. They can be interpreted as a “fingerprint” of various diseases. Nonetheless, MVs implementation into clinical settings has been hampered by the lack of technologies to accurately characterize, detect and quantify them. Here, we report the specific sensing and quantification of MVs from endothelial cells using a portable magnetoresistive (MR) biochip platform, in less than one hour and within physiologically relevant concentrations (1 × 108 MVs per ml). MVs were isolated from both endothelial and epithelial cells undergoing apoptosis, and characterized by atomic force microscopy (AFM) and nanoparticle tracking analysis (NTA), which revealed similar MV sizes. Importantly, our results showed that the two distinct MV populations could be discriminated with the MR biochip platform, with over a 5-fold capture efficiency of endothelial MVs in comparison to the control (epithelial MVs). Also, unspecific binding of MVs to BSA was less than 1% of the specific signal. The detection strategy was based on a sandwich immunoassay, where MVs were labelled with magnetic nanoparticles (MNPs) functionalized with Annexin V and then captured by anti-CD31 antibodies previously immobilized on the surface of the sensor. Results suggest that this approach allows the detection of specific MVs from complex samples such as serum, and highlight the potential of this technology to become a suitable tool for MVs detection as a complementary method of diagnosis.
- 21 February 2017
- Published by Royal Society of Chemistry (RSC) in The Analyst
- Vol. 142 (6) , 979-986
Rapid and specific detection of cell-derived microvesicles using a magnetoresistive biochip
Microvesicles (MVs) are a promising source of diagnostic biomarkers which have gained a wide interest in the biomedical and biosensing field. They can be interpreted as a “fingerprint” of various diseases. Nonetheless, MVs implementation into clinical settings has been hampered by the lack of technologies to accurately characterize, detect and quantify them. Here, we report the specific sensing and quantification of MVs from endothelial cells using a portable magnetoresistive (MR) biochip platform, in less than one hour and within physiologically relevant concentrations (1 × 108 MVs per ml). MVs were isolated from both endothelial and epithelial cells undergoing apoptosis, and characterized by atomic force microscopy (AFM) and nanoparticle tracking analysis (NTA), which revealed similar MV sizes. Importantly, our results showed that the two distinct MV populations could be discriminated with the MR biochip platform, with over a 5-fold capture efficiency of endothelial MVs in comparison to the control (epithelial MVs). Also, unspecific binding of MVs to BSA was less than 1% of the specific signal. The detection strategy was based on a sandwich immunoassay, where MVs were labelled with magnetic nanoparticles (MNPs) functionalized with Annexin V and then captured by anti-CD31 antibodies previously immobilized on the surface of the sensor. Results suggest that this approach allows the detection of specific MVs from complex samples such as serum, and highlight the potential of this technology to become a suitable tool for MVs detection as a complementary method of diagnosis.
- 13 November 2015
- Published by Royal Society of Chemistry (RSC) in Analytical Methods
- Vol. 8 (1) , 119-128
Implementing a strategy for on-chip detection of cell-free DNA fragments using GMR sensors: A translational application in cancer diagnostics using ALU elements
Optimization of a strategy for the detection of cell-free DNA using an array of magnetoresistive (MR) sensors integrated in a portable readout platform.
- 13 November 2015
- Published by Royal Society of Chemistry (RSC) in Analytical Methods
- Vol. 8 (1) , 119-128
Implementing a strategy for on-chip detection of cell-free DNA fragments using GMR sensors: A translational application in cancer diagnostics using ALU elements
Optimization of a strategy for the detection of cell-free DNA using an array of magnetoresistive (MR) sensors integrated in a portable readout platform.